Navigation Links
Xoft to Present at the 26th Annual JPMorgan Healthcare Conference
Date:1/3/2008

CEO to Provide Update on the Clinical and Commercial Adoption of the

Axxent(R) Electronic Brachytherapy System

FREMONT, Calif., Jan. 3 /PRNewswire/ -- Xoft, Inc., developer of the Axxent(R) Electronic Brachytherapy System, a proprietary cancer treatment platform that utilizes X-rays to deliver non-radioactive, isotope-free radiation therapy directly to cancer sites, today announced that it will present at the 26th Annual JPMorgan Healthcare Conference. Xoft president and CEO Michael Klein will present on Thursday, January 10, 2008, at 7:30am PST at The Westin St. Francis Hotel in San Francisco.

"We are excited to have the opportunity to provide an update on the adoption of this exciting new method of delivering internal radiation therapy since we went fully commercial in Q4 of 2007," said Klein. "With breast cancer, the first FDA cleared indication for the Axxent System, we are already seeing excellent clinical results at the 10 initial clinical sites and more than a dozen commercial sites that have committed since we went commercial. Combined with strong awareness among the oncology community and the recent establishment of Medicare payment for Electronic Brachytherapy in the outpatient hospital setting, we expect rapid and widespread commercial adoption, making it available to women who want to take advantage of breast conserving therapy."

Cleared by the U.S. Food & Drug Administration (FDA) for the treatment of early stage breast cancer, the Axxent System is designed to deliver therapy directly to cancer sites with minimal radiation exposure to surrounding healthy tissue. Eliminating the need for heavily shielded environments, it gives radiation oncologists the flexibility to deliver therapy in a broader range of clinical settings.

Use of the Axxent Electronic Brachytherapy System also provides the opportunity to reduce the time required for radiation therapy for early stage breast cancer from seven weeks (for external radiation therapy) down to five days. As a result, tens of thousands of patients will have greater access to therapy that is delivered more easily and conveniently. This may accelerate patient choice of breast sparing lumpectomy surgery with adjuvant radiation therapy over the alternative of a full mastectomy.

The American Medical Association (AMA) Common Procedural Terminology (CPT) Editorial Panel recently approved a CPT Code for the use of electronic brachytherapy. Effective July 2007, the CPT code for electronic brachytherapy is included in the AMA CPT 2008 codebook. Additionally, the Category III CPT Code 0182T: high dose rate electronic brachytherapy, per fraction, has been assigned a New Technology Ambulatory Payment Classification (APC). The APC payment applies to the outpatient hospital and ambulatory surgical center settings and includes the high dose rate electronic brachytherapy radiation treatment and the cost of the X-ray source.

About Xoft, Inc.

Xoft is developing leading-edge new technologies for the practice of radiation oncology through Electronic Brachytherapy, which utilizes proprietary miniaturized x-ray tube technology. The Axxent(R) Electronic Brachytherapy System, Xoft's first treatment system, is currently being used in Accelerated Partial Breast Irradiation (APBI) for the treatment of early-stage breast cancer. This solution provides a therapeutic dose of intracavitary radiation directly to the region at risk without the complex handling and resource logistics necessary when performing brachytherapy using radioactive isotopes.

Axxent is a registered trademark of Xoft, Inc.


'/>"/>
SOURCE Xoft, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Danaher to Present at J.P. Morgan Healthcare Conference
2. Ikaria to Present at 26th Annual JPMorgan Healthcare Conference
3. Thoratec Presentation at JP Morgan Conference to be Webcast
4. Caliper Life Sciences to Present at JPMorgan 26th Annual Healthcare Conference
5. Medarex to Present at the 26th Annual JPMorgan Healthcare Conference
6. CryoLife to Present at OneMedPlace Finance Forum
7. Exelixis Announces January 10 Webcast of Presentation at the 26th Annual JPMorgan Healthcare Conference
8. Onyx Pharmaceuticals to Present at JPMorgan Healthcare Conference
9. Nektar Therapeutics President and CEO Howard W. Robin to Present At JPMorgan 26th Annual Healthcare Conference
10. Beckman Coulter to Present at the JPMorgan Healthcare Conference
11. Thermo Fisher Scientific to Present at the 26th Annual JPMorgan Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/20/2017)... , ... June 20, 2017 , ... ... Robbie, PhD, a well-versed leader with extensive assay development and biomarker expertise, as ... Biomedical is a Boston CRO specializing in bio-analytical assay development and sample testing ...
(Date:6/19/2017)... ... 2017 , ... As Vice President, Product Services, Mr. Guinter ... support, and client process and SOP development. , Mr. Guinter brings a wealth ... for service providers and top-tier pharmaceuticals, and as an independent consultant supported a ...
(Date:6/19/2017)... Iowa (PRWEB) , ... June 19, 2017 , ... A ... interplay among its cells and tissues by delivering pollen and nectar containing nutrients necessary ... the means to stay healthy. , Many recent indicators point to a decline in ...
(Date:6/16/2017)... (PRWEB) , ... June 16, 2017 , ... CTNext ... Entrepreneur Innovation Awards (EIA), held at The LOFT at Chelsea Piers in Stamford. , ... ideas to a panel of judges for an opportunity to secure $10,000 awards to ...
Breaking Biology Technology:
(Date:4/11/2017)... April 11, 2017 No two people ... at the New York University Tandon School of ... have found that partial similarities between prints are ... in mobile phones and other electronic devices can ... The vulnerability lies in the fact that fingerprint-based ...
(Date:4/5/2017)... April 5, 2017  The Allen Institute for Cell ... Explorer: a one-of-a-kind portal and dynamic digital window into ... data, the first application of deep learning to create ... cell lines and a growing suite of powerful tools. ... these and future publicly available resources created and shared ...
(Date:4/4/2017)... April 4, 2017   EyeLock LLC , a ... the United States Patent and Trademark Office (USPTO) has ... the linking of an iris image with a face ... represents the company,s 45 th issued patent. ... very timely given the multi-modal biometric capabilities that have ...
Breaking Biology News(10 mins):